Scholarlink

Purpose <p>To evaluate the prognostic value of early post-treatment <sup>18</sup>F-FDG PET/CT in diffuse large B-cell lymphoma (DLBCL) patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy.</p> Methods <p>In this retrospective study, 159 patients referred for imaging prior to CAR-T therapy between January 2018 and May 2023 were reviewed. Of those, 51 with both baseline pre-infusion and one-month post-treatment <sup>18</sup>F-FDG PET/CTs were included. <sup>18</sup>F-FDG PET/CT parameters were derived, including standard uptake values (SUVs), metabolic tumour volume (MTV), total lesion glycolysis (TLG), and Dmax. Additionally, the delta changes from the baseline were calculated. Time to progression/death was documented. For progression-free survival (PFS) and overall survival (OS), univariate analysis was performed using the Kaplan-Meier method. The significance of the difference was measured using the Mantel-Cox log-rank test. Significant parameters entered the multiple Cox regression.</p> Results <p>Overall, 51 patients (mean age = 56y) entered the study. All had Deauville scores of 4 (14/51; 28%) or 5 (37/51; 72%) at baseline. At one month, 28% of patients showed a complete metabolic response, while 72% had <sup>18</sup>F-FDG-avid significant residual disease. Investigating those with residual disease, SUVmax, SUVpeak, SUVmax-to-Liver ratio and MTV were significantly lower in the one-month post-treatment scan. For PFS evaluation, serum LDH, one-month post-treatment SUVmax-to-liver ratio, one-month post-treatment TLG, and baseline Dmax entered the multivariate analysis. The one-month post-treatment SUVmax-to-liver ratio (Hazard ratio [HR] = 5.21; <i>p</i> = 0.004) and baseline Dmax (HR = 13.8; <i>p</i> = 0.013) retained significance, being independent predictors of PFS. For OS, serum LDH, delta SUVmean-to-liver ratio, delta percentage TLG, and one-month post-treatment Dmax were included in the multivariate analysis. The delta percentage TLG (HR = 4.37; <i>p</i> = 0.023) remained significant as an independent predictor of OS.</p> Conclusion <p>Early post-treatment <sup>18</sup>F-FDG PET/CT can provide valuable prognostic information for DLBCL patients receiving CAR-T. The most significant predictors of outcomes would be the baseline extent of the disease, one-month post-treatment avidity, and changes in the metabolic burden from baseline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of early post-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月8日

查看全文
  • Seyed Ali Mirshahvalad,
  • Andres Kohan,
  • Roshini Kulanthaivelu,
  • Claudia Ortega,
  • Ur Metser,
  • David Hodgson,
  • Robert Kridel,
  • Christine Chen,
  • Sita Bhella,
  • Kelly Yuen Wai Chin,
  • Patrick Veit-Haibach

摘要

Purpose

To evaluate the prognostic value of early post-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma (DLBCL) patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy.

Methods

In this retrospective study, 159 patients referred for imaging prior to CAR-T therapy between January 2018 and May 2023 were reviewed. Of those, 51 with both baseline pre-infusion and one-month post-treatment 18F-FDG PET/CTs were included. 18F-FDG PET/CT parameters were derived, including standard uptake values (SUVs), metabolic tumour volume (MTV), total lesion glycolysis (TLG), and Dmax. Additionally, the delta changes from the baseline were calculated. Time to progression/death was documented. For progression-free survival (PFS) and overall survival (OS), univariate analysis was performed using the Kaplan-Meier method. The significance of the difference was measured using the Mantel-Cox log-rank test. Significant parameters entered the multiple Cox regression.

Results

Overall, 51 patients (mean age = 56y) entered the study. All had Deauville scores of 4 (14/51; 28%) or 5 (37/51; 72%) at baseline. At one month, 28% of patients showed a complete metabolic response, while 72% had 18F-FDG-avid significant residual disease. Investigating those with residual disease, SUVmax, SUVpeak, SUVmax-to-Liver ratio and MTV were significantly lower in the one-month post-treatment scan. For PFS evaluation, serum LDH, one-month post-treatment SUVmax-to-liver ratio, one-month post-treatment TLG, and baseline Dmax entered the multivariate analysis. The one-month post-treatment SUVmax-to-liver ratio (Hazard ratio [HR] = 5.21; p = 0.004) and baseline Dmax (HR = 13.8; p = 0.013) retained significance, being independent predictors of PFS. For OS, serum LDH, delta SUVmean-to-liver ratio, delta percentage TLG, and one-month post-treatment Dmax were included in the multivariate analysis. The delta percentage TLG (HR = 4.37; p = 0.023) remained significant as an independent predictor of OS.

Conclusion

Early post-treatment 18F-FDG PET/CT can provide valuable prognostic information for DLBCL patients receiving CAR-T. The most significant predictors of outcomes would be the baseline extent of the disease, one-month post-treatment avidity, and changes in the metabolic burden from baseline.